%0 Journal Article
%T Evaluation of staged autologous blood transfusion during extracorporeal membrane oxygenation decannulation: A retrospective study.
%A Gao Y
%A Chen X
%A Mei Y
%A Yang T
%A Huang X
%A Zhang H
%A Gao Y
%A Sun F
%A Zhang H
%A Ji X
%A Wu J
%J Heart Lung
%V 68
%N 0
%D 2024 Jul 22
%M 39043085
%F 3.149
%R 10.1016/j.hrtlng.2024.07.009
%X <B>BACKGROUND: </B>Clinical blood resources are scarce and autologous blood transfusion for extracorporeal membrane oxygenation (ECMO) withdrawal is less studied.<BR><B>OBJECTIVE: </B>To assess the use of staged autotransfusion during ECMO decannulation.<BR><B>METHODS: </B>The study included ECMO withdrawal patients. Patients in the autologous transfusion group underwent staged transfusion during ECMO withdrawal, while those in the control group received 2.0 units of allogeneic packed red blood cells (RBCs) to increase hemoglobin (Hb). Parameters such as Hb, hematocrit (Hct), adverse events, decannulation success rate, volume of allogeneic RBC transfusions, and transfusion costs were compared.<BR><B>RESULTS: </B>A total of 82 Chinese patients were enrolled, with a mean age of 46 years, 27 were female, and the top three primary diagnoses were cardiac arrest, acute myocarditis, and severe pneumonia. There were 41 individuals in the autologous blood transfusion group and 41 in the control group. No significant differences were observed in Hb, Hct, adverse events, and the success rate for decannulation between the two groups (all P > 0.05). Compared with the control group, the volume of allogeneic RBC transfusions [0 (0∼1.50) U vs. 3.5 (1.88∼40) U, P < 0.001] and the total cost [130 (130∼390) Chinese Yuan (CNY) vs. 910 (487.50, 1040) CNY, P = 0.002] were lower in the autologous transfusion group.<BR><B>CONCLUSIONS: </B>In comparison with allogeneic RBC transfusion, staged autotransfusion during ECMO decannulation not only effectively maintained Hb levels but also reduced the requirement for allogeneic RBC transfusions. In addition, this approach decreased the associated costs and did not increase the risk of clinical adverse events.